Immix Biopharma (IMMX) Competitors $2.65 -0.07 (-2.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.64 0.00 (-0.19%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. AARD, BNTC, HRTX, AVIR, SGMT, MREO, NMRA, SCPH, MNPR, and EDITShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Aardvark Therapeutics (AARD), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), scPharmaceuticals (SCPH), Monopar Therapeutics (MNPR), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Aardvark Therapeutics Benitec Biopharma Heron Therapeutics Atea Pharmaceuticals Sagimet Biosciences Mereo BioPharma Group Neumora Therapeutics scPharmaceuticals Monopar Therapeutics Editas Medicine Immix Biopharma (NASDAQ:IMMX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings. Which has better valuation & earnings, IMMX or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$21.61M-$0.70-3.79Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A Is IMMX or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -130.02% -86.33% Aardvark Therapeutics N/A N/A N/A Does the media refer more to IMMX or AARD? In the previous week, Aardvark Therapeutics had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 2 mentions for Aardvark Therapeutics and 1 mentions for Immix Biopharma. Aardvark Therapeutics' average media sentiment score of 0.92 beat Immix Biopharma's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IMMX or AARD? Immix Biopharma currently has a consensus price target of $7.00, indicating a potential upside of 164.15%. Aardvark Therapeutics has a consensus price target of $33.00, indicating a potential upside of 172.05%. Given Aardvark Therapeutics' higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in IMMX or AARD? 11.3% of Immix Biopharma shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryAardvark Therapeutics beats Immix Biopharma on 7 of the 9 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.83M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-3.7917.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book5.528.508.275.54Net Income-$21.61M-$55.06M$3.25B$259.28M7 Day Performance-2.21%-3.99%-3.70%-4.64%1 Month Performance9.96%9.58%4.34%4.41%1 Year Performance23.83%6.70%25.90%17.95% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma2.6353 of 5 stars$2.65-2.6%$7.00+164.2%+27.4%$75.83MN/A-3.799News CoverageAARDAardvark TherapeuticsN/A$14.16+3.0%$33.00+133.1%N/A$307.27MN/A0.0018BNTCBenitec Biopharma1.5873 of 5 stars$11.55+2.5%$26.00+125.2%+30.0%$303.21M$80K-7.6520Positive NewsHRTXHeron Therapeutics3.7275 of 5 stars$1.96+2.9%$5.00+155.8%-39.9%$298.26M$144.29M-32.58300AVIRAtea Pharmaceuticals1.692 of 5 stars$3.45+0.4%$6.00+74.2%-4.4%$294.82MN/A-2.0970News CoverageUpcoming EarningsSGMTSagimet Biosciences2.9703 of 5 stars$9.57-0.4%$26.60+178.1%+137.1%$293.97M$2M-5.458MREOMereo BioPharma Group1.3786 of 5 stars$1.83+3.7%$7.20+294.5%-58.3%$290.18M$10M-26.0740NMRANeumora Therapeutics2.4207 of 5 stars$1.77-6.6%$7.14+304.7%-87.6%$287.91MN/A-1.11108Upcoming EarningsGap DownSCPHscPharmaceuticals3.8033 of 5 stars$5.41+0.5%$14.00+159.0%+7.9%$285.54M$36.33M-2.8330News CoverageMNPRMonopar Therapeutics1.9638 of 5 stars$46.73+3.3%$60.00+28.4%+1,074.0%$285.45MN/A-13.4110Upcoming EarningsEDITEditas Medicine3.9706 of 5 stars$3.43+1.9%$4.70+37.2%-52.5%$285.12M$32.31M-1.12230News CoverageUpcoming Earnings Related Companies and Tools Related Companies Aardvark Therapeutics Competitors Benitec Biopharma Competitors Heron Therapeutics Competitors Atea Pharmaceuticals Competitors Sagimet Biosciences Competitors Mereo BioPharma Group Competitors Neumora Therapeutics Competitors scPharmaceuticals Competitors Monopar Therapeutics Competitors Editas Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMMX Stock Alerts